Connect with us

Health

Emyria and partner Mind Medicine Australia launch psychedelic-assisted therapy program targeting PTSD – Proactive Investors Australia

EMDMA-001 has been modelled on a major Phase III clinical trial developed by the Multidisciplinary Association for Psychedelic Studies (MAPS).

Published

on

Article feature image

EMDMA-001 has been modelled on a major Phase III clinical trial developed by the Multidisciplinary Association for Psychedelic Studies (MAPS). Emyria Ltd (ASX:EMD) and partner Mind Medicine Australia have launched the EMDMA-001 psychedelic-assisted therapy program targeting sufferers of treatment-resistant post-traumatic stress disorder (PTSD).
As a first step, and pending ethics approval, Emyria, an innovative drug development and clinical services company, will sponsor a major, independently monitored,…

Click here to view the original article.

Continue Reading
Advertisement

You might also like ...

Article feature image
UK readies for major reopening but new variant sparks worry – The Chronicle Journal
Article feature image
The #1 Cause of Depression, According to Science | Eat This Not That – Eat This, Not That